{"version":"1.0","type":"link","title":"Trajectory timelines and treatment efficacy of Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center.","author_name":"Pouliot F 외","author_url":"https://prs-insight.online/author/Pouliot%20F","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/132142","thumbnail_width":1200,"thumbnail_height":630}